p16 Expression Correlates with Invasive Ocular Surface Squamous Neoplasms in HIV-Infected Mozambicans.
HIV
Human papillomavirus
Ocular surface squamous neoplasia
p16 immunohistochemistry
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
20
03
2019
accepted:
12
07
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
ppublish
Résumé
p16 immunohistochemistry is widely used to diagnose human papillomavirus (HPV)-related squamous neoplasms of cervix, anogenital, head, and neck tissues. The incidence of these HPV-related squamous neoplasms is markedly increased in the HIV-infected population. Ocular surface squamous neoplasia (OSSN) is also more common in HIV-infected patients. However, the expression pattern of p16 in OSSN among HIV-infected patients is unclear. Here, we examined the expression of p16 in OSSN surgical excisions collected from a large HIV-infected cohort from -Mozambique. OSSN surgical tissue specimens were collected from 75 Mozambican patients. Formalin-fixed, paraffin-embedded tissue blocks from these OSSNs were sectioned, stained with hematoxylin and eosin (H&E), and p16 expression by immunohistochemistry. H&E slides were reviewed to determine if OSSNs were noninvasive conjunctival intraepithelial neoplasms or invasive squamous cell carcinomas (SCC). Cases were classified as p16 positive or negative based on diffuse nuclear and cytoplasmic expression of p16 in neoplastic cells. p16 positivity was found in a minority of OSSN cases (14/75). p16 positivity was significantly associated with the invasive SCC type of OSSN in HIV-infected patients ( The majority of OSSNs in our HIV-infected cohort do not express p16. However, those cases that are p16-positive are significantly more likely to be the invasive SCC form of OSSN. We propose that p16 expression may identify more aggressive OSSNs in HIV-infected populations.
Sections du résumé
BACKGROUND
BACKGROUND
p16 immunohistochemistry is widely used to diagnose human papillomavirus (HPV)-related squamous neoplasms of cervix, anogenital, head, and neck tissues. The incidence of these HPV-related squamous neoplasms is markedly increased in the HIV-infected population. Ocular surface squamous neoplasia (OSSN) is also more common in HIV-infected patients. However, the expression pattern of p16 in OSSN among HIV-infected patients is unclear. Here, we examined the expression of p16 in OSSN surgical excisions collected from a large HIV-infected cohort from -Mozambique.
METHODS
METHODS
OSSN surgical tissue specimens were collected from 75 Mozambican patients. Formalin-fixed, paraffin-embedded tissue blocks from these OSSNs were sectioned, stained with hematoxylin and eosin (H&E), and p16 expression by immunohistochemistry. H&E slides were reviewed to determine if OSSNs were noninvasive conjunctival intraepithelial neoplasms or invasive squamous cell carcinomas (SCC). Cases were classified as p16 positive or negative based on diffuse nuclear and cytoplasmic expression of p16 in neoplastic cells.
RESULTS
RESULTS
p16 positivity was found in a minority of OSSN cases (14/75). p16 positivity was significantly associated with the invasive SCC type of OSSN in HIV-infected patients (
CONCLUSIONS
CONCLUSIONS
The majority of OSSNs in our HIV-infected cohort do not express p16. However, those cases that are p16-positive are significantly more likely to be the invasive SCC form of OSSN. We propose that p16 expression may identify more aggressive OSSNs in HIV-infected populations.
Identifiants
pubmed: 32258020
doi: 10.1159/000502096
pii: oop-0006-0123
pmc: PMC7109427
doi:
Types de publication
Journal Article
Langues
eng
Pagination
123-128Subventions
Organisme : FIC NIH HHS
ID : D43 TW010135
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Br J Cancer. 2007 May 7;96(9):1480-3
pubmed: 17437020
Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8069-78
pubmed: 24255045
Br J Ophthalmol. 1997 Apr;81(4):308-13
pubmed: 9215061
Blood. 2014 May 15;123(20):3105-15
pubmed: 24622326
Oncogene. 2011 May 5;30(18):2087-97
pubmed: 21297668
Surv Ophthalmol. 1995 May-Jun;39(6):429-50
pubmed: 7660300
Cancer Lett. 2006 Jul 28;239(1):98-102
pubmed: 16143449
Head Neck Pathol. 2012 Jul;6 Suppl 1:S75-82
pubmed: 22782226
Cell Cycle. 2011 Aug 1;10(15):2497-503
pubmed: 21775818
Neoplasia. 2006 Jun;8(6):429-36
pubmed: 16820088
PeerJ. 2018 Mar 22;6:e4407
pubmed: 29593938
Medicine (Baltimore). 2019 Jan;98(2):e13944
pubmed: 30633172
J Ophthalmic Vis Res. 2016 Oct-Dec;11(4):415-421
pubmed: 27994810
Br J Ophthalmol. 2018 Jun;102(6):840-847
pubmed: 29511060
Br J Cancer. 2013 Oct 1;109(7):1981-8
pubmed: 24030075
Br J Ophthalmol. 2002 Feb;86(2):168-73
pubmed: 11815342
Curr Eye Res. 2009 Aug;34(8):666-71
pubmed: 19899994
Int J Oncol. 2019 May;54(5):1503-1510
pubmed: 30896784
Diagn Pathol. 2015 Sep 24;10:175
pubmed: 26400483
Br J Cancer. 2010 Jan 19;102(2):262-7
pubmed: 19997105
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4
pubmed: 8633069
Am J Pathol. 1998 Dec;153(6):1741-8
pubmed: 9846965
Br J Ophthalmol. 2006 Jul;90(7):894-9
pubmed: 16540490
Am J Clin Pathol. 2002 Mar;117(3):429-36
pubmed: 11888082
Eur J Cancer Prev. 2013 Nov;22(6):566-8
pubmed: 23752127
Cornea. 1987;6(2):78-116
pubmed: 3301209
Cornea. 2013 Oct;32(10):1354-8
pubmed: 23974890
Eye (Lond). 2012 Feb;26(2):202-11
pubmed: 22134594
Int J Cancer. 2012 Aug 15;131(4):949-55
pubmed: 21960453
Exp Eye Res. 2014 Dec;129:172-82
pubmed: 25447808
N Engl J Med. 1989 Jun 1;320(22):1442-6
pubmed: 2541337
Curr Opin Oncol. 2013 Sep;25(5):503-10
pubmed: 23852381
Ophthalmology. 2002 Mar;109(3):542-7
pubmed: 11874759
HIV AIDS (Auckl). 2018 Mar 14;10:33-45
pubmed: 29559813
Cancer. 2010 May 1;116(9):2166-73
pubmed: 20186832
Br J Ophthalmol. 1996 Jun;80(6):503-8
pubmed: 8759259
Am J Clin Pathol. 2004 Dec;122(6):938-43
pubmed: 15539387
Invest Ophthalmol Vis Sci. 1992 Jan;33(1):184-9
pubmed: 1309728
Br J Cancer. 2002 Jul 29;87(3):301-8
pubmed: 12177799